Skip to content
Head to head

Praxis Precision Medicines vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PRAX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

PRAX +52.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
PRAXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price300.43515.02
Change today-3.37%-1.08%
1-year return+83.1%+22.0%
Market cap$8.40B$130.58B
52-week range167.32 – 392.70412.27 – 568.67
Valuation
P/E (TTM)-23.4333.14
P/E percentile, own 5-yr range3rd99th
P/B6.676.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-13.4815.32
Net profit (TTM)$-376.79M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-3927.5%33.1%
Net margin-3658.5%30.7%
Free cash flow (TTM)$-323.62M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership126.9%96.8%
Insider activity (12mo)35 buy / 15 sell28 buy / 22 sell
Short interest (% of float)15.1%1.9%
Analyst consensus92% buy / 8% hold (12)95% buy / 5% hold (21)
Analyst price target$728 (+142%)$624 (+21%)
StockVane view
StockVane Quant RatingD (90)C (68)
Company
Employees1686,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.